Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Sialic acid binding Ig like lectin 20, pseudogene (SIGLEC20P), is a **pseudogene** belonging to the Siglec (Sialic acid-binding immunoglobulin-like lectin) family, which normally encodes cell surface proteins involved in immune cell signaling and recognition of sialylated glycan structures[3][4][5]. However, SIGLEC20P lacks protein-coding capacity and does not produce a functional receptor; thus it does not participate in signal transduction, disease mechanisms, or drug interactions typical of active Siglecs. As a pseudogene, it is not considered a therapeutic target, and functional information, biomarker utility, and safety concerns do not apply[2][7][8]. Alternative names include SIGLECP1 and SIGLECP4. There is something inherently "incorrect" about treating SIGLEC20P as a genuine therapeutic target, since pseudogenes by definition generally lack biological function and do not encode active protein products[6]. Thus, SIGLEC20P is not a receptor, enzyme, transporter, or other druggable entity, and efforts to develop therapies targeting it would be scientifically inappropriate.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sialic acid binding Ig like lectin 20, pseudogene (SIGLEC20P).